Literature DB >> 33258046

[Preoperative radiochemotherapy improves oncological results in borderline resectable pancreatic cancer, but not overall survival in resectable cancers : Results from the Dutch PREOPANC study].

Robert Michael Hermann1, Hans Christiansen2.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 33258046      PMCID： PMC7801343          DOI： 10.1007/s00066-020-01717-6

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  5 in total

1.  FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.

Authors:  Thierry Conroy; Pascal Hammel; Mohamed Hebbar; Meher Ben Abdelghani; Alice C Wei; Jean-Luc Raoul; Laurence Choné; Eric Francois; Pascal Artru; James J Biagi; Thierry Lecomte; Eric Assenat; Roger Faroux; Marc Ychou; Julien Volet; Alain Sauvanet; Gilles Breysacher; Frédéric Di Fiore; Christine Cripps; Petr Kavan; Patrick Texereau; Karine Bouhier-Leporrier; Faiza Khemissa-Akouz; Jean-Louis Legoux; Béata Juzyna; Sophie Gourgou; Christopher J O'Callaghan; Claire Jouffroy-Zeller; Patrick Rat; David Malka; Florence Castan; Jean-Baptiste Bachet
Journal:  N Engl J Med       Date:  2018-12-20       Impact factor: 91.245

2.  Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial.

Authors:  Jin-Young Jang; Youngmin Han; Hongeun Lee; Sun-Whe Kim; Wooil Kwon; Kyung-Hun Lee; Do-Youn Oh; Eui Kyu Chie; Jeong Min Lee; Jin Seok Heo; Joon Oh Park; Do Hoon Lim; Seong Hyun Kim; Sang Jae Park; Woo Jin Lee; Young Hwan Koh; Joon Seong Park; Dong Sup Yoon; Ik Jae Lee; Seong Ho Choi
Journal:  Ann Surg       Date:  2018-08       Impact factor: 12.969

3.  Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial.

Authors:  Janet E Murphy; Jennifer Y Wo; David P Ryan; Wenqing Jiang; Beow Y Yeap; Lorraine C Drapek; Lawrence S Blaszkowsky; Eunice L Kwak; Jill N Allen; Jeffrey W Clark; Jason E Faris; Andrew X Zhu; Lipika Goyal; Keith D Lillemoe; Thomas F DeLaney; Carlos Fernández-Del Castillo; Cristina R Ferrone; Theodore S Hong
Journal:  JAMA Oncol       Date:  2018-07-01       Impact factor: 31.777

Review 4.  Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer.

Authors:  E Versteijne; J A Vogel; M G Besselink; O R C Busch; J W Wilmink; J G Daams; C H J van Eijck; B Groot Koerkamp; C R N Rasch; G van Tienhoven
Journal:  Br J Surg       Date:  2018-04-30       Impact factor: 6.939

5.  R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-007± trial.

Authors:  R Fietkau; R Grützmann; U A Wittel; R S Croner; L Jacobasch; U P Neumann; A Reinacher-Schick; D Imhoff; S Boeck; L Keilholz; H Oettle; W M Hohenberger; H Golcher; W O Bechstein; W Uhl; A Pirkl; W Adler; S Semrau; S Rutzner; M Ghadimi; D Lubgan
Journal:  Strahlenther Onkol       Date:  2020-09-10       Impact factor: 3.621
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.